About ADCs targeting TROP2, conjugation of the irinotecan metabolite, SN-38, to a humanized anti-TROP2 antibody (sacituzumab govitecan) promotes broad and potent antitumor effects in human cancer xenografts and in patients with advanced triple-negative breast, non-small-cell and small-cell lung, and urothelial cancers (14). This evidence concerns the gene TACSTD2 and cancer.